J. Safra Sarasin Holding Ag Madrigal Pharmaceuticals, Inc. Transaction History
J. Safra Sarasin Holding Ag
- $5.52 Trillion
- Q1 2025
A detailed history of J. Safra Sarasin Holding Ag transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Safra Sarasin Holding Ag holds 1,792 shares of MDGL stock, worth $512,028. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,792
Previous 3,405
47.37%
Holding current value
$512,028
Previous $1.05 Billion
43.51%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding MDGL
# of Institutions
367Shares Held
23.3MCall Options Held
979KPut Options Held
459K-
Janus Henderson Group PLC London, X02.21MShares$630 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$600 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$578 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$570 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$564 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.89B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...